JP5690068B2 - 環状染色体コンホメーション捕捉（４ｃ） - Google Patents
環状染色体コンホメーション捕捉（４ｃ） Download PDFInfo
- Publication number
- JP5690068B2 JP5690068B2 JP2009545253A JP2009545253A JP5690068B2 JP 5690068 B2 JP5690068 B2 JP 5690068B2 JP 2009545253 A JP2009545253 A JP 2009545253A JP 2009545253 A JP2009545253 A JP 2009545253A JP 5690068 B2 JP5690068 B2 JP 5690068B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- sequence
- sequences
- nucleotide sequence
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000349 chromosome Anatomy 0.000 title claims description 288
- 239000002773 nucleotide Substances 0.000 claims description 296
- 125000003729 nucleotide group Chemical group 0.000 claims description 296
- 108020004414 DNA Proteins 0.000 claims description 279
- 108091008146 restriction endonucleases Proteins 0.000 claims description 252
- 238000000034 method Methods 0.000 claims description 213
- 230000003993 interaction Effects 0.000 claims description 206
- 230000005945 translocation Effects 0.000 claims description 164
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 140
- 239000013615 primer Substances 0.000 claims description 125
- 230000008707 rearrangement Effects 0.000 claims description 112
- 108090000623 proteins and genes Proteins 0.000 claims description 108
- 238000012217 deletion Methods 0.000 claims description 106
- 230000037430 deletion Effects 0.000 claims description 106
- 238000009396 hybridization Methods 0.000 claims description 98
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 87
- 238000012163 sequencing technique Methods 0.000 claims description 84
- 201000010099 disease Diseases 0.000 claims description 78
- 210000004027 cell Anatomy 0.000 claims description 63
- 238000004458 analytical method Methods 0.000 claims description 62
- 238000001514 detection method Methods 0.000 claims description 48
- 238000003491 array Methods 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 238000013461 design Methods 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 16
- 238000001976 enzyme digestion Methods 0.000 claims description 16
- 238000012165 high-throughput sequencing Methods 0.000 claims description 16
- 239000003155 DNA primer Substances 0.000 claims description 14
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- -1 silencer Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 238000012408 PCR amplification Methods 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 210000002230 centromere Anatomy 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 230000010354 integration Effects 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 238000005215 recombination Methods 0.000 claims description 9
- 230000010076 replication Effects 0.000 claims description 9
- 108091035539 telomere Proteins 0.000 claims description 9
- 102000055501 telomere Human genes 0.000 claims description 9
- 210000003411 telomere Anatomy 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 claims description 7
- 102100023876 Rhombotin-2 Human genes 0.000 claims description 7
- 101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 claims description 7
- 101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 claims description 7
- 102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 claims description 7
- 239000012212 insulator Substances 0.000 claims description 7
- 230000003252 repetitive effect Effects 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 claims description 6
- 101000958299 Homo sapiens Protein lyl-1 Proteins 0.000 claims description 6
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 claims description 6
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 claims description 6
- 101000625330 Homo sapiens T-cell acute lymphocytic leukemia protein 2 Proteins 0.000 claims description 6
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 6
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 6
- 102100038231 Protein lyl-1 Human genes 0.000 claims description 6
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims description 6
- 102100025039 T-cell acute lymphocytic leukemia protein 2 Human genes 0.000 claims description 6
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 238000007403 mPCR Methods 0.000 claims description 5
- 230000003584 silencer Effects 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 101100395211 Trichoderma harzianum his3 gene Proteins 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 description 339
- 239000012634 fragment Substances 0.000 description 164
- 238000005516 engineering process Methods 0.000 description 150
- 238000003752 polymerase chain reaction Methods 0.000 description 90
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 62
- 230000002759 chromosomal effect Effects 0.000 description 61
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 56
- 230000001605 fetal effect Effects 0.000 description 56
- 230000003321 amplification Effects 0.000 description 55
- 238000003199 nucleic acid amplification method Methods 0.000 description 55
- 239000000047 product Substances 0.000 description 51
- 210000004185 liver Anatomy 0.000 description 48
- 102000004190 Enzymes Human genes 0.000 description 36
- 108090000790 Enzymes Proteins 0.000 description 36
- 239000000126 substance Substances 0.000 description 35
- 239000000975 dye Substances 0.000 description 34
- 210000004556 brain Anatomy 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 33
- 238000002493 microarray Methods 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 238000007852 inverse PCR Methods 0.000 description 29
- 230000002068 genetic effect Effects 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 26
- 239000013610 patient sample Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 22
- 238000013459 approach Methods 0.000 description 22
- 230000000295 complement effect Effects 0.000 description 22
- 238000004132 cross linking Methods 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 230000005856 abnormality Effects 0.000 description 21
- 230000007423 decrease Effects 0.000 description 21
- 239000013068 control sample Substances 0.000 description 20
- 238000012216 screening Methods 0.000 description 19
- 108010077544 Chromatin Proteins 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000003483 chromatin Anatomy 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 238000002372 labelling Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000008520 organization Effects 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 230000029087 digestion Effects 0.000 description 11
- 238000007363 ring formation reaction Methods 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 230000002103 transcriptional effect Effects 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 208000031404 Chromosome Aberrations Diseases 0.000 description 8
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 8
- 101150112539 OR gene Proteins 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108091008875 B cell receptors Proteins 0.000 description 7
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 7
- 101001003569 Homo sapiens LIM domain only protein 3 Proteins 0.000 description 7
- 102100026460 LIM domain only protein 3 Human genes 0.000 description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000003426 interchromosomal effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000008045 co-localization Effects 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000003793 prenatal diagnosis Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008711 chromosomal rearrangement Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 108091008053 gene clusters Proteins 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 4
- 208000035970 Chromosome Breakpoints Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108091012583 BCL2 Proteins 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 208000027205 Congenital disease Diseases 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101150090099 LMO3 gene Proteins 0.000 description 3
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108050002069 Olfactory receptors Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 231100000005 chromosome aberration Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000008863 intramolecular interaction Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 238000002205 phenol-chloroform extraction Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241001244729 Apalis Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 101150017888 Bcl2 gene Proteins 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 101710093638 LIM domain only protein 3 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000012547 Olfactory receptors Human genes 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027522 Sydenham chorea Diseases 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000015608 reproductive system cancer Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000007450 ChIP-chip Methods 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010011017 Corneal graft rejection Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- ZFIVKAOQEXOYFY-UHFFFAOYSA-N Diepoxybutane Chemical compound C1OC1C1OC1 ZFIVKAOQEXOYFY-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101710112457 Exoglucanase Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150008172 HOXA9 gene Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 101150028321 Lck gene Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028182 Multiple congenital abnormalities Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001098666 Pterois volitans Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 102100024869 Rhombotin-1 Human genes 0.000 description 1
- 101710096623 Rhombotin-1 Proteins 0.000 description 1
- 101710096632 Rhombotin-2 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000011622 Testicular disease Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 102000022628 chromatin binding proteins Human genes 0.000 description 1
- 108091013410 chromatin binding proteins Proteins 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 101150097231 eg gene Proteins 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 108010089558 erythroid Kruppel-like factor Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007902 molecular cytogenetic technique Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000017954 parathyroid gland carcinoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 208000003580 polydactyly Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 231100000622 toxicogenomics Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 208000024523 vestibulocochlear nerve neoplasm Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6823—Release of bound markers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99975007P | 2007-01-11 | 2007-01-11 | |
| US60/999,750 | 2007-01-11 | ||
| US97790007P | 2007-10-05 | 2007-10-05 | |
| US60/977,900 | 2007-10-05 | ||
| PCT/IB2008/000625 WO2008084405A2 (en) | 2007-01-11 | 2008-01-10 | Circular chromosome conformation capture (4c) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010515449A JP2010515449A (ja) | 2010-05-13 |
| JP2010515449A5 JP2010515449A5 (enExample) | 2011-02-24 |
| JP5690068B2 true JP5690068B2 (ja) | 2015-03-25 |
Family
ID=39609120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545253A Active JP5690068B2 (ja) | 2007-01-11 | 2008-01-10 | 環状染色体コンホメーション捕捉（４ｃ） |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8642295B2 (enExample) |
| EP (1) | EP2121977B1 (enExample) |
| JP (1) | JP5690068B2 (enExample) |
| CN (1) | CN101688237A (enExample) |
| AU (1) | AU2008204338B2 (enExample) |
| BR (1) | BRPI0806565A2 (enExample) |
| DK (1) | DK2121977T3 (enExample) |
| ES (1) | ES2634266T3 (enExample) |
| PT (1) | PT2121977T (enExample) |
| WO (1) | WO2008084405A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1899488B1 (en) * | 2005-07-04 | 2015-09-16 | Erasmus University Medical Center | Chromosome conformation capture-on-chip (4c) assay |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US9074244B2 (en) * | 2008-03-11 | 2015-07-07 | Affymetrix, Inc. | Array-based translocation and rearrangement assays |
| CN102712954A (zh) * | 2009-11-06 | 2012-10-03 | 小利兰·斯坦福大学托管委员会 | 器官移植患者移植排斥的非侵入性诊断 |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| PT2591125T (pt) * | 2010-07-09 | 2018-05-09 | Cergentis B V | Estratégias 3-d de sequenciação de regiões genómicas de interesse |
| AU2012211957B2 (en) | 2011-02-04 | 2017-02-23 | The Trustees Of The University Of Pennsylvania | A method for detecting chromosome structure and gene expression simultaneously in single cells |
| CA2824387C (en) | 2011-02-09 | 2019-09-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| HK1199745A1 (en) | 2011-09-09 | 2015-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for obtaining a sequence |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US9411930B2 (en) | 2013-02-01 | 2016-08-09 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
| WO2014121091A1 (en) | 2013-02-01 | 2014-08-07 | The Regents Of The University Of California | Methods for genome assembly and haplotype phasing |
| EP2971278B1 (en) * | 2013-03-15 | 2022-08-10 | The Broad Institute, Inc. | Methods for determining multiple interactions between nucleic acids in a cell |
| KR101672531B1 (ko) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 |
| GB2517936B (en) * | 2013-09-05 | 2016-10-19 | Babraham Inst | Chromosome conformation capture method including selection and enrichment steps |
| EP3049557B1 (en) | 2013-09-27 | 2021-05-05 | University of Washington | Methods and systems for large scale scaffolding of genome assemblies |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| EP3561075A1 (en) | 2014-04-21 | 2019-10-30 | Natera, Inc. | Detecting mutations in tumour biopsies and cell-free samples |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| WO2016019360A1 (en) | 2014-08-01 | 2016-02-04 | Dovetail Genomics Llc | Tagging nucleic acids for sequence assembly |
| EP3201350B1 (en) | 2014-09-30 | 2020-12-02 | Global Life Sciences Solutions USA LLC | Method for nucleic acid analysis directly from an unpurified biological sample |
| WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| CA2970370A1 (en) | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
| CA2976902A1 (en) | 2015-02-17 | 2016-08-25 | Dovetail Genomics Llc | Nucleic acid sequence assembly |
| WO2016154540A1 (en) | 2015-03-26 | 2016-09-29 | Dovetail Genomics Llc | Physical linkage preservation in dna storage |
| WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
| EP4428863A3 (en) | 2015-05-11 | 2024-12-11 | Natera, Inc. | Methods and compositions for determining ploidy |
| EP3436575A1 (en) | 2015-06-18 | 2019-02-06 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| CA3012631A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| MY194686A (en) | 2015-06-24 | 2022-12-15 | Oxford BioDynamics PLC | Detection of chromosome interactions |
| WO2017061861A1 (en) * | 2015-10-05 | 2017-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Targeted locus amplification using cloning strategies |
| KR20180096586A (ko) | 2015-10-19 | 2018-08-29 | 더브테일 제노믹스 엘엘씨 | 게놈 어셈블리, 하플로타입 페이징 및 표적 독립적 핵산 검출을 위한 방법 |
| WO2017074788A1 (en) | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| SG11201807117WA (en) | 2016-02-23 | 2018-09-27 | Dovetail Genomics Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
| DK3443119T3 (da) | 2016-04-15 | 2022-05-23 | Natera Inc | Fremgangsmåde til bestemmelse af lunge cancer |
| KR102670601B1 (ko) | 2016-04-19 | 2024-05-29 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| US11286478B2 (en) | 2016-04-19 | 2022-03-29 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
| DK3455356T3 (da) | 2016-05-13 | 2021-11-01 | Dovetail Genomics Llc | Genfinding af langtrækkende bindingsinformation fra konserverede prøver |
| US20210222164A1 (en) | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| ES2971286T3 (es) * | 2016-12-01 | 2024-06-04 | Oxford BioDynamics PLC | Aplicación de interacciones cromosómicas epigenéticas en diagnóstico de cáncer |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| CA3047888C (en) | 2016-12-23 | 2025-05-27 | Oxford Biodynamics Ltd | METHOD FOR TYPING EPIGENETIC CHROMOSOME INTERACTIONS |
| CN107058484B (zh) * | 2016-12-26 | 2020-06-16 | 孙涛 | 一种应用于高通量测序同时检测t细胞和b细胞免疫组库的引物组合及试剂盒 |
| EP3612629A1 (en) | 2017-04-18 | 2020-02-26 | The Broad Institute, Inc. | Compositions for detecting secretion and methods of use |
| SG11202003233YA (en) * | 2017-11-03 | 2020-05-28 | Oxford BioDynamics PLC | Genetic regulation of immunoresponse by chromosome interactions |
| EP3714052A1 (en) | 2017-11-21 | 2020-09-30 | Arima Genomics, Inc. | Preserving spatial-proximal contiguity and molecular contiguity in nucleic acid templates |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12378592B2 (en) | 2018-01-31 | 2025-08-05 | Dovetail Genomics, Llc. | Sample prep for DNA linkage recovery |
| JP7573443B2 (ja) | 2018-04-14 | 2024-10-25 | ナテラ， インコーポレイテッド | 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法 |
| CN109033745A (zh) * | 2018-06-08 | 2018-12-18 | 中国农业科学院农业基因组研究所 | 一种消除三维基因组学技术噪音的方法及应用 |
| CN108804872A (zh) * | 2018-06-08 | 2018-11-13 | 中国农业科学院农业基因组研究所 | 利用外切酶组合消除三维基因组学技术噪音的方法及应用 |
| WO2020006370A1 (en) * | 2018-06-29 | 2020-01-02 | Grail, Inc. | Nucleic acid rearrangement and integration analysis |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US12421507B2 (en) | 2018-08-20 | 2025-09-23 | The Broad Institute, Inc. | Methods and compositions for optochemical control of CRISPR-CAS9 |
| CN113272441A (zh) | 2018-11-20 | 2021-08-17 | 阿瑞玛基因组学公司 | 保留空间邻近连续性信息的制备核酸的方法和组合物 |
| CN109609611A (zh) * | 2018-12-26 | 2019-04-12 | 上海优甲医疗科技有限公司 | 一种基于高通量测序技术的基因定量测序方法 |
| EP3973073A1 (en) | 2019-05-20 | 2022-03-30 | Arima Genomics, Inc. | Methods and compositions for enhanced genome coverage and preservation of spatial proximal contiguity |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| EP3980559A1 (en) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| JP2023523002A (ja) | 2020-04-23 | 2023-06-01 | コーニンクレッカ ネーデルラントセ アカデミー ファン ヴェッテンシャッペン | 染色体近接実験における構造的変異検出 |
| GB202111194D0 (en) * | 2021-08-03 | 2021-09-15 | Cergentis B V | Method |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) * | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) * | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| DE69233087T2 (de) | 1991-11-22 | 2003-12-24 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verfahren zur Herstellung von Polymerarrays |
| WO1995011995A1 (en) | 1993-10-26 | 1995-05-04 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5571639A (en) * | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| JP2000504575A (ja) | 1996-02-08 | 2000-04-18 | アフィメトリックス，インコーポレイテッド | 微生物のチップベースの種分化および表現型特徴付け |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| EP1483587A2 (en) * | 2002-03-08 | 2004-12-08 | The Babraham Institute | Tagging and recovery of elements associated with target molecules |
| EP1899488B1 (en) * | 2005-07-04 | 2015-09-16 | Erasmus University Medical Center | Chromosome conformation capture-on-chip (4c) assay |
-
2008
- 2008-01-10 EP EP08719319.9A patent/EP2121977B1/en active Active
- 2008-01-10 DK DK08719319.9T patent/DK2121977T3/en active
- 2008-01-10 ES ES08719319.9T patent/ES2634266T3/es active Active
- 2008-01-10 AU AU2008204338A patent/AU2008204338B2/en active Active
- 2008-01-10 BR BRPI0806565-9A patent/BRPI0806565A2/pt not_active Application Discontinuation
- 2008-01-10 CN CN200880008027A patent/CN101688237A/zh active Pending
- 2008-01-10 US US12/522,555 patent/US8642295B2/en active Active
- 2008-01-10 WO PCT/IB2008/000625 patent/WO2008084405A2/en not_active Ceased
- 2008-01-10 PT PT87193199T patent/PT2121977T/pt unknown
- 2008-01-10 JP JP2009545253A patent/JP5690068B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008084405A3 (en) | 2009-01-29 |
| WO2008084405A2 (en) | 2008-07-17 |
| AU2008204338A8 (en) | 2009-08-06 |
| BRPI0806565A2 (pt) | 2014-05-06 |
| PT2121977T (pt) | 2017-08-18 |
| EP2121977A2 (en) | 2009-11-25 |
| ES2634266T3 (es) | 2017-09-27 |
| AU2008204338A1 (en) | 2008-07-17 |
| DK2121977T3 (en) | 2017-09-18 |
| US8642295B2 (en) | 2014-02-04 |
| CN101688237A (zh) | 2010-03-31 |
| JP2010515449A (ja) | 2010-05-13 |
| AU2008204338B2 (en) | 2014-03-06 |
| EP2121977B1 (en) | 2017-06-21 |
| US20100062947A1 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5690068B2 (ja) | 環状染色体コンホメーション捕捉（４ｃ） | |
| DK1899488T3 (en) | CHROMOSOM CONFORMATIONS "CAPTURE-ON-CHIP" (4C) -ASSAY | |
| KR102592367B1 (ko) | 게놈 및 치료학적 적용을 위한 핵산 분자의 클론 복제 및 증폭을 위한 시스템 및 방법 | |
| CN102482719B (zh) | 使用阵列比较基因组杂交技术分析核酸突变的方法 | |
| CA2661640A1 (en) | Mapping of genomic interactions | |
| JP2004511236A (ja) | 核酸差異を含有するポリヌクレオチドを同定かつ単離する方法 | |
| JP2016537029A (ja) | 三次元ｄｎａ構造におけるヌクレオチド配列の相互作用を分析する方法 | |
| WO2000053806A1 (en) | Method of identifying gene transcription patterns | |
| US20070003929A1 (en) | Method for identifying, analyzing and/or cloning nucleic acid isoforms | |
| US20060228714A1 (en) | Nucleic acid representations utilizing type IIB restriction endonuclease cleavage products | |
| Class et al. | Patent application title: CIRCULAR CHROMOSOME CONFORMATION CAPTURE (4C) Inventors: Wouter De Laat (Rotterdam, NL) Frank Grosveld (Rotterdam, NL) Assignees: Erasmus University Medical Center | |
| CN101238225B (zh) | 染色体构象芯片捕获(4c)测定 | |
| HK1118870A (en) | Chromosome conformation capture-on-chip (4c) assay | |
| HK1118870B (en) | Chromosome conformation capture-on-chip (4c) assay | |
| CN101238225A (zh) | 染色体构象芯片捕获（4c）测定 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110106 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20110209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140822 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141014 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5690068 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |